

CURRICULUM VITAE

PERSONAL INFORMATION

Barry E. Bleske
60 Wind Road NW
Albuquerque, NM 87120

Telephone:(734) 223-2486

BUSINESS INFORMATION

University of New Mexico
College of Pharmacy
Pharmacy Practice & Administrative Sciences
2502 Marble NE
MSC09 5360
1 University of New Mexico
Albuquerque, NM 87131-0001

Telephone:(505) 272-1525
e-mail: bbleske@salud.unm.edu

ACADEMIC QUALIFICATIONS

1984-1986	Doctor of Pharmacy University of Minnesota College of Pharmacy Minneapolis, Minnesota
1979-1984	Bachelor of Science Wayne State University College of Pharmacy and Allied Health Professions Detroit, Michigan

PROFESSIONAL POSITIONS

2015-Present	Professor and Chair Department of Pharmacy Practice and Administrative Sciences University of New Mexico College of Pharmacy
2015 - Present	Professor Emeritus University of Michigan College of Pharmacy
2015	Professor University of Michigan College of Pharmacy
1995-2014	Associate Professor of Pharmacy University of Michigan College of Pharmacy Clinical Pharmacist Cardiology Service University of Michigan Hospital Ann Arbor, Michigan

1988-1995 Assistant Professor of Pharmacy
University of Michigan
College of Pharmacy

 Clinical Pharmacist
Cardiology Service
University of Michigan Hospital
Ann Arbor, Michigan

1986-1988 Post-Doctoral Pharmacy Fellow in Cardiovascular Therapeutics
Hartford Hospital, Hartford, Connecticut
Assistant Professor in Clinical Pharmacy
University of Connecticut, Storrs, Connecticut

1984-1985 Graduate Teaching Assistant, Drug Information Center
University of Minnesota, College of Pharmacy
Minneapolis, Minnesota

I. TEACHING ACTIVITY

1988-1999 P531-532, Therapeutics
1988-2010 P689-694, Clerkship Preceptor
1988-2015 P680-694, Seminar Preceptor
1989-1999 P562, Applied Pharmacokinetics, Course Coordinator and lecturer
1989-2015 P569, Pharm.D. Research Project Preceptor (Completed Projects)
60 students completed.

1990-1995 Instructor for College sponsored Cardiopulmonary Resuscitation Training Course for
Pharmacy Students

2000-2012 P532-Pathophysiology and Therapeutics, Course Coordinator and lecturer
2006-2010 P552 P-Care Lab, Course Coordinator and lecturer
2007-2009 P451 – Pharmaceutical Care Course P2 - Lecturer
2011-2015 P431 Therapeutic Problem Solving Course Coordinator and Lecturer
2011-2015 P432 Therapeutic Problem Solving Course Coordinator
2011-2015 P532 Therapeutic Problem Solving Course Lecturer
2012-2015 P554 Sports Medicine - Lecturer
2013-2015 P430 HTN lab
2013-2015 P563 PharmSci – Lecturer - CV Pharmacogenomics
2014 P476 Research Methods – Lecturer – IRB
2015-Present P785 Advanced Cardiology Elective
2015-2018 P764 Emerging Technology Lecturer
2015 IPE Community Engagement Course
2016 P751 Therapeutics IOR
2017 P704L – Pharmacy Care Lab IOR and Lecturer
2017-Present P803L – Aspects of Patient Care Lab IOR and Lecturer
2021-Present P835 Integrated Pharmacotherapy

II. CREATIVE ACTIVITIES

PUBLICATIONS

A. Research Articles - Refereed

1. Bleske BE, Larson TA, Rotschafer JC. Observed differences in amikacin pharmacokinetic parameters and dosage recommendations determined by fluorescent polarization immunoassay and enzyme immunoassay methods. *Ther Drug Monit* 1987;9:48-52
2. Bleske BE, Kluger J, Fisher JR, Chow MSS. Acute effects of combination of IB and IC antiarrhythmics for the treatment of ventricular tachycardia. *J Clin Pharmacol* 1989;29:998-1002
3. Bleske BE, Chow MSS, Zhao H, Kluger J, Fieldman A. Epinephrine vs methoxamine on survival post ventricular fibrillation and cardiopulmonary resuscitation in dogs. *Crit Care Med* 1989;17:1310-1313
4. Bleske BE, Kluger J, Colucci R, Chow MSS. Potassium and magnesium changes associated with programmed electrical stimulation. *J Electrophysiol* 1989;3:101-110
5. Bleske BE, Carver PL, Annesley TM, Bleske JRM, Morady F. The effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. *J Clin Pharmacol* 1990;30:911-915
6. Bleske BE, Warren EW, Rice TL, Shea MJ, Amidon G, Knight P. Comparison between intravenous and intranasal administration of epinephrine during cardiopulmonary resuscitation in a canine model. *Ann Emerg Med* 1992;21:1125-1130.
7. Bleske BE, Cornish LA, Boyd EL, Shimp LA, Shea MJ. Variability in drug administration times among patients with coronary artery disease. *J Pharm Technol* 1992;8:191-194.
8. Bleske BE, Chow MSS, Zhao H, Kluger J, Fieldman A. Effects of different dosages and modes of sodium bicarbonate administration during cardiopulmonary resuscitation. *Am J Emerg Med* 1992;10:525-532
9. Bleske BE, Rice TL, Warren EW, de las Alas VR, Tait AR, Knight PR. The effect of sodium bicarbonate administration on the vasopressor effect of high dose epinephrine during cardiopulmonary resuscitation in swine. *Am J Emerg Med* 1993;11:439-443
10. Bleske BE, Wheatley WK, Townsend KA, Guzzardo ML, Billi JE, Shea MJ. Drug therapy during cardiac arrest in two hospitals. *Am J Hosp Pharm* 1993;50:2538-254.
11. Bleske BE, Rice TL, Warren EW. An alternative sodium bicarbonate regimen during cardiac arrest and cardiopulmonary resuscitation in a canine model. *Pharmacotherapy* 1994;14:95-99
12. Mastroianni L, Low HB, Rollman J, Wagle M, Bleske B, Chow MSS. A comparison of 10% pentastarch and 5% albumin in patients undergoing open-heart surgery. *J Clin Pharmacol* 1994;34:34-40
13. Bleske BE, Welage LS, Touchette MA, Edwards DJ, Shea MJ. Evaluation of dosage release formulations on inhibition of drug clearance: The effect of sustained and immediate release verapamil on propranolol pharmacokinetic parameters. *Ther Drug Monit* 1994;16:216-220
14. Welage LS, Dunn-Kucharski VA, Berardi RR, Shea MJ, Dechert RE, Bleske BE. Comparative evaluation of the hemodynamic effect of oral cimetidine, ranitidine and famotidine as determined by echocardiography. *Pharmacotherapy* 1995;15:158-163
15. Guthrie SK, Wilde DW, Brown RA, Savage AO, Bleske BE. Interactions of ethanol and quinidine on contractility and myocyte action potential in rat ventricle. *Journal of Electrocardiology*.1995;28:39-47
16. Bleske BE, Welage LS, Rose S, Amidon GL, Shea MJ. The effect of dosage release formulations on the pharmacokinetics of propranolol stereoisomers in humans. *J Clin Pharmacol* 1995;35:374-378
17. Bleske BE, Warren EW, Rice TL, Gilligan LJ, Tait AR. Effect of high-dose sodium bicarbonate on the vasopressor effects of epinephrine during CPR. *Pharmacotherapy* 1995;15:660-664.
18. Bleske BE, Welage LS, Warren EW, Brown MB, Shea MJ. Variation in prothrombin times and INR over a 24 hours in warfarin treated patients. *Pharmacotherapy* 1995;15:709-712.
19. Bleske BE, Rice TL, Warren EW, Gilligan LJ, Massey K.D., Giacherio DA, Tait AR. Effect of dose on the nasal absorption of epinephrine during CPR. *Am J Emerg Med* 1996;14:133-138.
20. Bleske BE, Warren EW, Rice TL, Amidon G, Johnson K, Giacherio DA, Tait AR. Effect of vehicle on the nasal absorption of epinephrine and the histological effect on the nasal mucosa. *Pharmacotherapy* 1996;16:1039-1045.
21. Bleske BE, Cornish LA, Erickson SR, Nicklas JM. Evaluation of ACE-Inhibitor therapy for congestive heart failure in an outpatient setting. *J Pharm Technol* 1998;14:7-11.
22. Bleske BE, Welage LS, Kramer WG, Nicklas JM. Pharmacokinetics of tosemide in patients with decompensated and compensated congestive heart failure. *J Clin Pharmacol* 1998;38:708-714.
23. Bleske BE, Chung HS, DiMugno M, Nicklas JM. Diurnal variation in plasma norepinephrine in heart failure patients. *Pharmacotherapy* 1999;19:984-988.
24. Nicklas JM, Monsur JC, Bleske BE. Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. *Am J Cardiol* 1999;83:12(I)–15(I).

25. Strickberger SA, Bleske BE, Davidson T, Papasafakis EN, Pelosi F, Michaud GF, Knight BP, Morady F. Effect of ethanol on defibrillation energy requirements in humans. *Am J Cardiol* 2000;85:117-119.
26. Bleske BE, Willis RA, Anthony M, Casselberry N, Datwain M, Uhley VE, Secontine SG, Shea MJ. The effect of pravastatin and atorvastatin on coenzyme Q10. *Am Heart J* 2001;142:e2.
27. Bleske BE, Song J, Chow MSS, Kluger J, White CM. The hematological and chemical changes observed during and after cardiac arrest in a canine model – a pilot study. *Pharmacotherapy* 2001;21:1187-1191.
28. Tankanow R, Tamer HR, Streetman DS, Aaronson K, Bleske BE. Interaction Study Between Digoxin and a Preparation of Hawthorn (*Crataegus oxyacantha*). *Journal of Clinical Pharmacology* 2003;43:637-642.
29. Cirrincione GM, Boluyt MO, Hwang HS, Bleske BE. 3-Hydroxy-3-Methyl-Glytaryl Coenzyme A Reductase Inhibition and Extracellular Matrix Gene Expression in the Pressure-Overloaded Rat Heart. *Journal of Cardiovascular Pharmacology* 2006;47:521-530.
30. Bleske BE, Bard R, Nicklas JM, Pitt B. Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG – CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low density lipoproteins. *J Am Coll Cardiol* 2006;47:338-41.
31. Bleske BE, Hwang HS, Zineh I, Ghannam MG, Boluyt MO. Evaluation of immunomodulatory biomarkers in a pressure overload model of heart failure. *Pharmacotherapy* 2007;27(4):504-509.
32. Bleske BE, Zineh I, Hwang HS, Welder GJ, Ghannam MMJ, Boluyt MO. Evaluation of hawthorn extract on immunomodulatory biomarkers in a pressure overload model of heart failure. *Med Sci Monitor* 2007;13:BR255-258.
33. Hwang HS, Bleske BE, Ghannam MMJ, Converso K, Russell MW, Hunter JC, Boluyt MO. Effects of hawthorn on cardiac remodeling and left ventricular dysfunction after 1 month of pressure overload-induced cardiac hypertrophy in rats. *Cardiovasc Drugs Ther* 2008;22:19-28.
34. Wu Y, Zhang F, Wang Y, Krishnamoorthy MK, Roy-Chaudhury P, Bleske BE, Meyerhoff ME. Photoinstability of S-Nitrosothiols during sampling of whole blood: A likely source of error and variability in S-Nitrosothiol measurements. *Clin Chem* 2008;54:916-918.
35. Foster DR, Yee S, Bleske BE, Carver PL, Shea MJ, Menon SS, Ramachandran C, Welage LS, Amidon GL. Lack of interaction between the peptidomimetic substrates captopril and cephadrine. *J Clin Pharmacol*. 2009 Mar;49(3):360-7.
36. Hwang HS, Boluyt MO, Converso K, Russell MW, Ghannam MMJ, Bleske BE. Effects of hawthorn on the progression of heart failure in an aortic constriction model. *Pharmacotherapy* 2009;29:639-648.
37. Stout SM, Nielsen J, Bleske BE, Shea M, Brook R, Kerber K, Welage LS. The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. *J Cardiovasc Pharmacol Ther* 2010;15(4):373-9.
38. Stout SM, Nielsen J, Welage LS, Shea M, Brook R, Kerber K, Bleske BE. Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. *J Clin Pharmacol*. 2011; 51(3):389-962.
39. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: A retrospective cohort analysis. *Hypertension*. 2011 Apr;57(4):689-94.
40. Bleske BE, Erickson SR, Fahoum S, Devarakonda KR, Welage LS, Koudmani M, Pantham N, Edwin SB, Devarakonda S, Shea MJ, Martha S, Khalidi N. Cardiovascular risk among university students from developed and developing nations. *Open Cardiovasc Med J*. 2011;5:117-22.
41. Barnes M, Dorsch M, Aaronson K, Koelling T, Bleske BE. Baseline albumin predicts worsening renal function in acute decompensated heart failure patients receiving continuous infusion loop diuretics. *Pharmacotherapy*. 2013;33:583-8. PMID:23553379
42. Bleske BE, Barnes M, Wu A, Dorsch M. The effect of continuous infusion loop diuretics in acute decompensated heart failure patients with hypoalbuminemia. *J Cardiovasc Pharmacol Ther*. 2013;4:447-60.
43. Bleske BE, Remington TL, Wells TD, Dorsch MP, Guthrie SK, Stumpf JL, Alaniz MC, Ellingrod VL, Tingen JM. Comparing team based learning to traditional lecture on learning outcomes in a therapeutics course sequence. *Am J Pharm Educ*. 2014 Feb 12;78(1):13. doi: 10.5688/ajpe78113.
44. Dorsch MP, Nemerovski CW, Ellingrod V, Cowger JA, Dyke DB, Koelling TM, Wu AH, Aaronson K, Simpson RU, Bleske BE. The effect of vitamin D receptor genetics on extracellular matrix biomarkers and hemodynamics in systolic heart failure. *J Cardiovasc Pharmacol Ther*. 2014 Sep;19(5):439-45.
45. Bleske BE, Dillman NO, Cornelius D, Wark JK, Burson SC, Diez HL, Pickworth KK, Bennett MS, Nicklas JM, Dorsch MP. Heart Failure Assessment as the Community Pharmacy Level – A Feasibility Pilot Study.

- J Am Pharm Assoc 2014 Nov-Dec;54(6):634-41.
46. Remington TL, Hershock C, Klein KC, Niemer RK, Bleske BE. Lessons from the Trenches: Implementing Team-Based Learning Across Several Courses. *Currents in Pharmacy Teaching and Learning* 2015;7:121-130.
 47. Dorsch MP, Farris KB, Bleske BE, Koelling TM. A Web Application for Self-monitoring Improves Symptoms in Chronic Systolic Heart Failure. *Telemed J E Health*. 2015 Feb 5. [Epub ahead of print]
 48. Pressler SJ, Titler M, Koelling TM, Riley PL, Jung M, Hoyland-Domenico L, Ronis DL, Smith DG, Bleske BE, Dorsey SG, Giordani B. Nurse-Enhanced Computerized Cognitive Training Increases Serum Brain-Derived Neurotrophic Factor Levels and Improves Working Memory in Heart Failure. *J Card Fail*. 2015 21(8):630-41.
 49. Shi J, Wang X, Nguyen J, Wu AH, Bleske BE, Zhu HJ. Sacubitril is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation. *Drug Metab Dispos*. 2016 Apr;44(4):554-9. PMID: 26817948
 50. Bachyrycz A, Shrestha S, Bleske BE, Tinker D, Bakhireva LN. Opioid Overdose Prevention Through Pharmacy-based Naloxone Prescription Program: Innovations in Healthcare Delivery. *Subst Abus*. 2016 May 10:0. [Epub ahead of print]. PMID: 27164192
 51. Dorsch MP, Chong YP, McCormick MP, Grossi J, Kirchmeier L, Koelling T, Bleske BE. Survey of Computer, Smart Devices, and Internet use in Heart Failure Patients. *International Cardiovascular Forum Journal* 2016;6:84-85. DOI: 10.17987/icfj.v6i0.229
 52. Erickson SR, Spoutz P, Dorsch M, Bleske B. Cardiovascular Risk and Treatment for Adults with Intellectual or Developmental Disabilities. *Int J Cardiol*. 2016 Jul 5;221:371-375
 53. Shi J, Wang X, Nguyen JH, Bleske BE, Liang Y, Liu L, Zhu HJ. Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. *Biochem Pharmacol*. 2016 Nov 1;119:76-84
 54. Bleske BE, Remington TL, Wells TD, Klein KC, Guthrie SK, Tingen JM, Marshall VD, Dorsch MP. A Randomized Crossover Comparison between Team Based Learning and Lecture Format on Learning Outcomes. *Am J Pharm Educ*. 2016 Sep 25;80(7):120.
 55. Tyler CR, Zychowski KE, Sanchez BN, Rivero V, Lucas S, Herbert G, Liu J, Irshad H, McDonald JD, Bleske BE, Campen MJ. Surface area-dependence of gas-particle interactions influences pulmonary and neuroinflammatory outcomes. *Part Fibre Toxicol*. 2016 Dec 1;13(1):64
 56. Albabtain M, Brenner J, Nicklas J, Hummel S, McCormick M, Pawlowski J, Remington T, Gure T, Dorsch M, Bleske BE. Hyponatremia, Cognitive Function, and Mobility in an Ambulatory Heart Failure Population. *Med Sci Monit*. 2016 Dec 18;22:4978-4985.
 57. Hauptman PJ, Goff ZD, Vidic A, Chibnall JT, Bleske BE. Variability in Retail Pricing of Generic Drugs for Heart Failure. *JAMA Intern Med*. 2017 Jan 1;177(1):126-128.
 58. Kelling SE, Walker PC, Mason JG, Zara N, Bleske BE. Incorporation of a Community Pharmacy-Based Heart Failure Assessment Tool by Advanced Pharmacy Practice Experience Students. *J Am Pharm Assoc* 2017 May - Jun;57(3):382-388.
 59. Remington TL, Bleske BE, Bartholomew T, Dorsch MP, Guthrie SK, Klein KC, Tingen JM, Wells TD. Qualitative Analysis of Student Perceptions Comparing Team-based Learning and Traditional Lecture in a Pharmacotherapeutics Course. *Am J Pharm Educ*. 2017 Apr;81(3):55. doi: 10.5688/ajpe81355.
 60. Wang X, Rida N, Shi J, Wu AH, Bleske BE, Zhu HJ. A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms. *Drug Metab Dispos*. 2017 Nov;45(11):1149-1155.
 61. Koenigsknecht MJ, Baker JR, Wen B, Frances A, Zhang H, Yu A, Zhao T, Tsume Y, Pai MP, Bleske BE, Zhang X, Lionberger R, Lee A, Amidon GL, Hasler WL, Sun D. In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract under Fed and Fasted Conditions. *Mol Pharm*. 2017 Dec 4;14(12):4295-4304.
 62. Wang X, Liang Y, Shi J, Zhu HJ, Bleske BE. Crataegus Special Extract WS 1442 Effects on eNOS and microRNA 155. *Planta Med*. 2018 Apr 16. doi: 10.1055/a-0601-7083. [Epub ahead of print] PMID: 29660753
 63. Mohammad R, Ellingrod VL, Bleske BE. Implementing and Evaluating Virtual Patient Cases within a Team Based Learning Pedagogy in a Therapeutics Course Sequence. *J Am Coll Clin Pharm* 2018. DOI: 10.1002/jac5.1053
 64. Bleske BE, Remington TL, Wells TD, Klein KC, Tingen JM, Dorsch MP. A Randomized Crossover Comparison between Team Based Learning and Lecture Format on Long Term Learning Outcomes. *Pharmacy* 2018;6(3) PMID: 30081547

65. Takeda M, Wittstrom K, Bachyrycz A, Bleske BE. Opioid Overdose Response Training in Pharmacy Education: An Analysis of Students' Perception of Naloxone Use for Opioid Overdose Prevention. *Currents in Pharmacy Teaching and Learning* 2019;11:166-171.
66. Seekatz AM, Schnizlein MK, Koenigsnecht MJ, Baker JR, Hasler WL, Bleske BE, Young VB, Sun D. Spatial and Temporal Analysis of the Stomach and Small-Intestinal Microbiota in Fasted Healthy Humans. *mSphere*. 2019 Mar 13;4(2). pii: e00126-19. doi: 10.1128/mSphere.00126-19. PMID: 30867328.
67. Scoville BA, Segal JH, Salama NN, Heung M, Bleske BE, Eyler RF, Mueller BA. Single Dose Oral Ranolazine Pharmacokinetics in Patients Receiving Maintenance Hemodialysis. *Renal Failure* 2019;41:118-25.
68. Zychowski KE, Wheeler A, Sanchez B, Harmon M, Steadman Tyler CR, Herbert G, Lucas SN, Ali AM, Avasarala S, Kunda N, Robinson P, Mutil P, Cerrato JM, Bleske B, Smirnova O, Campen MJ. Toxic Effects of Particulate Matter Derived from Dust Samples Near the Dzhidinski Ore Processing Mill, Eastern Siberia, Russia. *Cardiovasc Toxicol*. 2019 Apr 8. doi: 10.1007/s12012-019-09507-y.
69. Zychowski KE, Tyler CRS, Sanchez B, Harmon M, Liu J, Irshad H, McDonald JD, Bleske BE, Campen MJ. Vehicular Particulate Matter (PM) Characteristics Impact Vascular Outcomes Following Inhalation. *Cardiovasc Toxicol*. 2019 Aug 13. doi: 10.1007/s12012-019-09546-5. [Epub ahead of print] PMID: 31410643.
70. Anderson JR, Hunter T, Dinallo JM, Glaser D, Roybal LK, Segovia A, Raley R, Bleske BE. Population Screening for Atrial Fibrillation by Student Pharmacists at Health Fairs. *J Am Pharm Assoc* (2003). 2020 Jan 31. pii: S1544-3191(20)30003-0. doi: 10.1016/j.japh.2019.12.021. [Epub ahead of print] PMID: 32014442
71. Begay J, Sanchez B, Wheeler A, Baldwin F Jr, Lucas S, Herbert G, Ordonez Suarez Y, Shuey C, Klaver Z, Harkema JR, Wagner JG, Morishita M, Bleske B, Zychowski KE, Campen MJ. Assessment of particulate matter toxicity and physicochemistry at the Claim 28 uranium mine site in Blue Gap, AZ. *J Toxicol Environ Health A*. 2021 Jan 2;84(1):31-48. doi: 10.1080/15287394.2020.1830210. Epub 2020 Oct 13. PMID: 33050837
72. Garcia M, Salazar R, Wilson T, Lucas S, Herbert G, Young T, Begay J, Denson JL, Zychowski K, Ashley R, Byrum S, Mackintosh S, Bleske BE, Ottens AK, Campen MJ. Early Gestational Exposure to Inhaled Ozone Impairs Maternal Uterine Artery and Cardiac Function. *Toxicol Sci*. 2021 Jan 6;179(1):121-134. doi: 10.1093/toxsci/kfaa164. PMID: 33146391
73. Wittstrom KW, Godwin DA, Bleske BE. Intervention and remediation: A descriptive study of practices in pharmacy education. *Curr Pharm Teach Learn*, 2020. Online ahead of print. ISSN 1877-1297. <https://doi.org/10.1016/j.cptl.2020.10.012>.

B. Review Articles/Guidelines - Refereed

1. Bleske BE. Esmolol. *Connecticut Medicine* 1987;51:669-671.
2. Bleske BE, Shea M. Current concepts of silent myocardial ischemia. *Clin Pharm* 1990;9:339-357.
3. Bleske BE, Billi JE. Comparison of adrenergic agonists for the treatment of ventricular fibrillation and pulseless electrical activity. *Resuscitation* 1994;28:239-251.
4. Pentz WH, Bleske B, Nicklas JM. Hemodynamic versus clinical management of congestive heart failure. *Clinical research* 1994;42(3):A368-A368.
5. Bleske BE, Gilbert EM, Munger MA. Carvedilol: Therapeutic Application and Practice Guidelines. *Pharmacotherapy* 1998;18:729-737.
6. Bleske BE. Evolution and the pathophysiology of chronic systolic heart failure. *Pharmacotherapy* 2000;20:349S-358S.
7. Chavey WE, Blaum CS, Bleske BE, Harrison RV, Kesterson S, Nicklas JM. Guideline for the management of heart failure caused by systolic dysfunction. Guideline development, etiology and diagnosis. *American Family Physician* 2001;64:769-774.
8. Chavey WE, Blaum CS, Bleske BE, Harrison RV, Kesterson S, Nicklas JM. Guideline for the management of heart failure caused by systolic dysfunction. Treatment. *American Family Physician* 2001;64:1045-54.
9. Chavey WE, Bleske BE, Nicklas JM. Controversies in the use of beta blockers in heart failure. *CHF* 2003;9:255-262.
10. Bard RL, Bleske BE, Nicklas JM. Food: An unrecognized source of loop diuretic resistance. *Pharmacotherapy* 2004;24:630-637.

11. Bleske BE. The “PROMISE” of a Good Hypothesis: Statins and CoQ10 Therapy. *Current Topics in Nutraceutical Research* 2005;3:159-162.
12. Ito MK, Cheung RJ, Gupta EK, Birtcher KK, Chong PH, Bianco TM, Bleske BE. Key articles, guidelines, and consensus papers relative to the treatment of dyslipidemias – 2005. *Pharmacotherapy* 2006;26:939-1010.
13. Chavey WE, Bleske BE, Harrison RV, Hogikyan RV, Kesterson SK, Nicklas JM. Pharmacological management of heart failure caused by systolic dysfunction. *Am Fam Physician* 2008;77:957-964.
14. Dunn SP, Bleske BE, Dorsch MP, Macaulay T, Van Tassell B, Vardeny O. Nutrition and Heart Failure: Impact of drug therapies and management strategies. *Nutr Clin Pract.* 2009 Feb-Mar;24(1):60-75.
15. Nemerovski C, Dorsch M, Simpson R, Bone H, Aaronson K, Bleske BE. Vitamin D and Cardiovascular Disease. *Pharmacotherapy* 2009;29:691-708.
16. Chow SL, Dorsch MP, Dunn SP, Jackevicius CA, Page RL 2nd, Trujillo T, Vardeny O, Wiggins B, Bleske BE. Key articles related to complementary and alternative medicine in cardiovascular disease: part 1. *Pharmacotherapy.* 2010 Jan;30(1):109.
17. Barnes MM, Dorsch MP, Hummel SL, Koelling TM, Bleske BE. Treatment of Heart Failure with Preserved Ejection Fraction. *Pharmacotherapy* 2011;31(3):312–331.
18. Chow SL, Singh H, DiDomenico RJ, Dunn SP, Johnson SG, Marrs JC, Vardeny O, Bleske BE. Key Articles Related to Complementary and Alternative Medicine in Cardiovascular Disease: Part II. *Pharmacotherapy* 2011;31(10):1041. DOI: 10.1592/phco.31.10.1041
19. Shuster JE, Bleske BE, Dorsch MP. Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension. *Vasc Health Risk Manag* 2012;8: 1–7.
20. Nicklas JM, Bleske BE, Van Harrison R, Hogikyan RV, Kwok Y, Chavey WE. Heart failure: clinical problem and management issues. *Prim Care.* 2013 Mar;40(1):17-42.
21. Lose JM, Dorsch MP, Bleske BE. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering. *Pharmacotherapy* 2013;33:447-60.
22. Chavey WE, Bleske BE, Harrison RV, Hogikyan RV, Kwok Y, Nicklas JM, Koelling TM. Heart Failure – Systolic Dysfunction. Ann Arbor, MI: Office of Clinical Affairs, University of Michigan Health Systems 2013. [Available from the Agency for Healthcare Research and Quality at www.guideline.gov] [practice guideline].
23. Walter CP, Bleske BE, and Dorsch MP. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents. *Journal of Clinical Pharmacy and Therapeutics.* 2014 Oct;39(5):475-84. PMID: 24924286.

C. Book Chapters

1. Shea MJ, Bleske BE, Santinga JK, Das SK. Heart Disease in Pregnancy. Chapter 29. In: Sciarra JJ, et al, eds. *Gynecology & Obstetrics.* Harper & Row, Inc. 1991.
2. Bleske BE, Billi JE. CPR - Focus on Drug Therapy. *Pharmacotherapy Self Assessment Program Third Edition. Module I, Cardiovascular,* 1998. American College of Clinical Pharmacy, Kansas City, MO.
3. Bleske BE, Koch E, Aaronson K, Boluyt MO. Hawthorn and Heart Disease. Chapter 51. In: *Botanical Medicine in Clinical Practice,* edited by R. R. Watson and V. R. Preedy. CABI Publishing – 2008.
4. Bleske BE, Cox Z, Vardney O. Pharmacogenomics of Lipid Lowering Drugs with a Focus on SLC01B and Statin Therapy. In Johnson JA, et al, eds. “Pharmacogenomics. Application to Patient Care” 3rd edition. American College of Clinical Pharmacy, Kansas City, MO, 2015. ISBN: 978-1-939862-09-9.
5. Cox Z, Bleske BE. Heart Failure with Preserved Ejection Fraction. CardSAP Chapter, American College of Clinical Pharmacy, Kansas City, MO. May 2019; ISBN-13: 978-1-939862-75-4

D. Editorials and Commentaries

1. Zhanel GG, Bleske BE. Conversion from intravenous lidocaine to oral tocainide (letter). *JAMA* 1986;255:3361-62
2. Bates ER, Wei CL, Bleske BE. Loading, pretreatment, and interindividual variability issues with clopidogrel dosing. *Circulation* 2005;111:2557-2559.

E. Non-refereed Professional Publications

1. Bleske BE, Chow MSS. Current therapeutic approaches for angina pectoris. *US Pharmacist* 1989;14:38-59.
2. Bleske BE. *Hospital Pharmacy Simulations in Cardiovascular Medicine*. Sponsored by Marion Merrell Dow Inc. Medical Age Publishing Company, Rowayton, Connecticut, 1990.
3. Cornish LA, Bleske BE. *Hospital Pharmacy Simulations in Cardiovascular Medicine*. Sponsored by Marion Merrell Dow Inc. Medical Age Publishing Company, Rowayton, Connecticut, 1995.
4. Pharmacy Today Publication - Study finds wide variability in price of generic heart failure medications. February, 2017.

F. Abstracts/Poster Presentations

1. Bleske BE, Larson TA, Rotschafer JC. Differences observed between fluorescent polarization immunoassay and enzyme immunoassay methods in the determination of amikacin pharmacokinetic parameters and dosage recommendations. Presented at Minnesota Society of Hospital Pharmacists Continuing Education Conference. 1986.
2. Bleske BE, Kluger J, Chow MSS, Regnier J. Clinical, electrophysiological, and adverse effects of amiodarone in patients with refractory ventricular tachycardia. Presented at 22nd Annual ASHP Midyear Clinical Meeting, Atlanta, Georgia 1987.
3. Mastroianni L, Low H, Rollman J, Bleske J, Bleske BE, Chow MSS. Hemodynamic effects of pentastarch vs albumin in post open-heart surgery patients. Presented at 89th Annual American Society for Clinical Pharmacology and Therapeutics Meeting, San Diego, CA 1988.
4. Mastroianni L, Low H, Rollman J, Bleske J, Bleske BE, Chow MSS. Pentastarch is as effective as albumin in maintaining hemodynamic stability in post open heart surgery patients. Presented at the Society of Cardiovascular Anesthesiologists 10th Annual Meeting, New Orleans, LA 1988.
5. Colucci RD, Kluger J, Zhao H, Regnier J, Bleske BE, Chow MSS. Acute clinical and electrophysiological effects of encainide in patients with ventricular tachycardia. Presented at the 9th Annual Meeting of the American College of Clinical Pharmacy, Philadelphia, PA 1988.
6. Bleske BE, Kluger J, Chow MSS. Time course of potassium and magnesium concentrations during electrophysiological testing. Presented at the 17th Annual American College of Clinical Pharmacology, Orlando, FL 1988.
7. Bleske BE, Kluger J, Regnier J, Chow MSS. Acute response to combination of IB and IC antiarrhythmics. Presented at the 17th Annual American College of Clinical Pharmacology, Orlando, FL 1988.
8. Bleske BE, Kluger J, Chow MSS, Fieldman A, Zhao H. Epinephrine and methoxamine vs diltiazem post cardiac arrest and resuscitation in dogs. Presented at the 17th Annual American College of Clinical Pharmacology, Orlando, FL 1988.
9. Bleske BE, Chow MSS, Kluger J, Zhao H, Fieldman A. Effects of different modes of sodium bicarbonate administration during cardiopulmonary resuscitation. Presented at the 90th Annual American Society for Clinical Pharmacology and Therapeutics, Nashville, Tennessee, March 1989.
10. Bleske BE, Carver PL, Bleske JR, Annesley TM, Morady F. Effect of ciprofloxacin on the pharmacokinetic and ECG parameters of quinidine. Presented at the 11th Annual Meeting of the American College of Clinical Pharmacy, August 5-8, 1990, San Francisco, CA. *Pharmacotherapy* 1990;10:246.
11. Townsend KA, Cornish L, Bleske BE. Serum digoxin concentration utilization review. Presented at the 1990 ASHP Midyear Clinical Meeting, Las Vegas, Nevada.
12. Carver PL, Bleske BE, Sinko PJ, Partipilo ML, Thoene D, Amidon GL. The effect of captopril on the absorption of cephadrine in human subjects. Presented at the 12th Annual Meeting of the American College of Clinical Pharmacy, August 18-21, 1991, Minneapolis, MN. *Pharmacotherapy* 1991;11:275.
13. Bleske BE, Warren EW, Rice TL, Shea M, Knight P. Comparison between intravenous and intranasal administration of epinephrine during cardiopulmonary resuscitation in a canine model. Presented at the 12th Annual Meeting of the American College of Clinical Pharmacy, August 18-21, 1991, Minneapolis, MN. *Pharmacotherapy* 1991;11:280.
14. Townsend KA, Guzzardo ML, Wheatley W, Bleske BE. Advanced cardiac life support - a drug use evaluation. Presented at the 1991 ASHP Midyear Clinical Meeting, New Orleans, LA.

15. Bleske BE, Welage LS, Touchette MA, Edwards DJ, Rodman D, Shea MJ. Comparison of the effect of immediate and sustained release verapamil on the pharmacokinetic parameters of propranolol. Presented at the 1992 Winter Practice and Research Forum, American College of Clinical Pharmacy, February 9-12, 1992, Phoenix, Arizona. *Pharmacotherapy* 1991;11:P-36.
16. Dunn-Kucharski VA, Welage LS, Berardi RR, Shea MJ, Bleske BE. Comparative evaluation of the hemodynamic effects of cimetidine, ranitidine and famotidine as determined by echocardiography. Presented at the 1992 Winter Practice and Research Forum, American College of Clinical Pharmacy, February 9-12, 1992, Phoenix, Arizona. *Pharmacotherapy* 1991;11:P-37.
17. Bleske BE. The effect of sodium bicarbonate administration on the vasopressor effect of high dose epinephrine during cardiopulmonary resuscitation in swine. Oral presentation, 1992 Annual Meeting of the American College of Clinical Pharmacy, August 9-12, 1992, Toronto, Ontario, CAN.
18. Bleske BE, Rice TL, Warren EW. Investigation of an alternate sodium bicarbonate regimen during ventricular fibrillation and cardiopulmonary resuscitation in a canine model. Presented at the 1993 Winter Practice and Research Forum, American College of Clinical Pharmacy, February 7-10, 1993, Ft. Lauderdale, Florida. *Pharmacotherapy* 1992;12:500 (33).
19. Guthrie SK, Wilde DW, Bleske BE. The effects of quinidine on cardiac myocyte action potential are antagonized by ethanol. Presented at the 94th Annual Meeting of the American Society For Clinical Pharmacology and Therapeutics, Honolulu, Hawaii, March 24-26, 1993. *Clin Pharmacol Ther* 1993;53:176 (PII-26).
20. Williams A, Bleske B, Giacherio D, Bajwa H, Stemmer K, Waidley M, Das S, Moore C, Brown M, Nicklas J. Reproducibility and etiology of the diurnal variability in plasma potassium levels in patients with congestive heart failure. Presented at the American College of Cardiology 42nd Annual Scientific Session, Anaheim, California, March 14-18, 1993.
21. Bleske BE, Nicklas JM. Evaluation of the variability in hourly magnesium levels in congestive heart failure patients treated with high dose diuretics and in age-matched controls. Presented at the 14th Annual Meeting of the American College of Clinical Pharmacy, Reno, Nevada, August 15-18, 1993. *Pharmacotherapy* 1993;13:270.
22. Welage LS, Shea MJ, Amidon GL, Bleske BE. The influence of dosage forms on the pharmacokinetics of R and S propranolol. Presented at the Fourth Annual Winter Practice and Research Forum of the American College of Clinical Pharmacy, San Diego, California, February 6-9, 1994. *Pharmacotherapy* 1994;13:683.
23. Bleske BE, Rice TL, Warren EW, Gilligan L, Tait AR. Nasal administration of epinephrine during CPR. Presented at the 24th Annual Michigan Cardiovascular Research Forum, Ann Arbor, Michigan, September 20, 1994.
24. Rice TL, Warren EW, Bleske BE. Vasopressor effects of epinephrine during CPR with extreme alkalemia. Presented at the 1995 Winter Practice and Research Forum, American College of Clinical Pharmacy, February 12-15, 1995, Orlando, Florida.
25. Welage LS, Warren EW, Bleske BE. Diurnal variation in prothrombin times and INR. Presented at the 1995 Winter Practice and Research Forum, American College of Clinical Pharmacy, February 12-15, 1995, Orlando, Florida.
26. Bleske BE, Warren EW, Gilligan LJ, Massey KD, Tait AR, Rice TL. Effect of dose on the nasal absorption of epinephrine during CPR. Presented at the 1995 Winter Practice and Research Forum, American College of Clinical Pharmacy, February 12-15, 1995, Orlando, Florida.
27. Bleske BE, Rice TL, Warren EW, Giacherio DA, Gilligan LJ, Massey KD, Chrisp CE, Tait AR. Effect of vehicle on the nasal absorption of epinephrine during cardiopulmonary resuscitation. Presented at the 1996 Winter Practice and Research Forum, American College of Clinical Pharmacy, February 11-14, 1996, Monterey, California. *Pharmacotherapy* 1996;16:125.
28. Welage LS, Neudeck BL, Iteld L, Bleske BE, Rice TL, et al. Evaluation of the pharmacokinetics of caffeine in trauma patients as compared to healthy volunteers. Presented at the 1997 Spring Practice and Research Forum of the American College of Clinical Pharmacy, April 6-9, 1997, Panama City, Florida.
29. Bleske BE, Welage LS, Kramer WG, Nicklas JM. Torsimide pharmacokinetics in patients with decompensated and compensated congestive heart failure. Presented at the 1997 Spring Practice and Research Forum, American College of Clinical Pharmacy, April 6-9, 1997, Panama City, FL.
30. Neudeck BL, Bleske BE, Rice TL, et al. Xanthine Oxidase, N-acetyltransferase-2, and P4501A2 activity in trauma patients as compared to healthy volunteers: use of caffeine as a marker substrate. Presented at the

- 1997 Annual Meeting of the American College of Clinical Pharmacy, November 9-12, 1997, Phoenix, Arizona.
31. Bleske BE, Chung HS, Nicklas JM. Variation in plasma norepinephrine levels in heart failure patients. Presented at the 1998 Spring Practice and Research Forum of the American College of Clinical Pharmacy, April 5 - 8, 1998, Palm Springs, California.
 32. Nicklas JM, Bleske BE, Brown M, Stemmer K, Waidley MR, Das SK, Giacherio DA. Nocturnal hypokalemia in patients with congestive heart failure treated with diuretics. Presented at the 71st Scientific Session of the American Heart Association. *Circulation* 1998;98:I-24.
 33. Bleske BE, Leung J, Chaffee BW. Loop diuretic effectiveness for the treatment of heart failure: the first 24 hours. Oral presentation at International Congress on Clinical Pharmacy, April 11-14, 1999, Orlando, Florida. *Pharmacotherapy* 1999;19:478.
 34. Bleske BE, Willis RA, Casselberry N, Datwani M, Anthony M, Shea MJ. The effect of pravastatin and atorvastatin on coenzyme Q10. Presented at 2000 Spring Practice and Research Forum, American College of Clinical Pharmacy, Monterey, California, April 4, 2000.
 35. Bleske BE, Zhang M, Bard R, Nicklas JM. The effect of HMG-CoA reductase inhibitors on exercise capacity in congestive heart failure. Presented at 2001 Spring Practice and Research Forum, American College of Clinical Pharmacy, Salt Lake City, Utah, April 24, 2001. *Pharmacotherapy* 2001;21:367.
 36. Tankanow R, Tamer HR, Streetman DS, Smith SG, Wlaton JL, Annesley T, Aaronson KD, Bleske BE. Hawthorn effects on digoxin's ECG parameters. Presented at 2002 Spring Practice and Research Forum, American College of Clinical Pharmacy, Savannah, Georgia, April 9, 2002. *Pharmacotherapy* 2002;22:411.
 37. Bleske BE. The effect of digoxin and hawthorn on myocyte contractility. American College of Clinical Pharmacy, Palm Springs, California, April 29, 2003. *Pharmacotherapy* 2003;23:392
 38. Bleske BE, Bard R, Nicklas JM, Pitt B. Neutral Effect on Surrogate Markers of Heart Failure Following High Dose HMG – CoA Reductase Inhibition in Non-Diabetic Patients with Non-Ischemic Cardiomyopathy and Average Low Density Lipoproteins. *Cytokines and Inflammation*, GTIC Bio Conference, San Francisco, CA, January 26-27, 2005.
 39. Bleske BE, Cirrincione GM, Hwang HS, Boluyt MO. HMG-CoA reductase inhibition and gene expression in the pressure-overloaded rat heart. American College of Clinical Pharmacy, 2005 Spring Practice and Research Forum, Myrtle Beach, South Carolina, April 10, 2005. *Pharmacotherapy* 2005;25:455 (16)
 40. Myers EJ, Nolan PE, Slack M, Bleske BE. HMG –CoA reductase inhibitors reduce all-cause mortality in patients with established heart failure: a meta-analysis. American College of Clinical Pharmacy 2007 Annual Meeting, Denver, Colorado. *Pharmacotherapy* 2007; 192(30).
 41. Meyerhoff ME, Wu Y, Cha W, Zhang F, Bleske B: Electrochemical Sensors for Measuring S-Nitrosothiol Species in Whole Blood: Design and Potential POC Applications. *Point of Care: The Journal of Near-Patient Testing & Technology*: September 2008 - Volume 7 - Issue 3 - p 137.
 42. Dorsch MP, Erickson SR, Bleske BE, et al. Improved nonfatal cardiovascular events with chlorthalidone compared to hydrochlorothiazide; American Society of Hypertension 2010 Scientific Meeting; May 2, 2010; New York, NY. Abstract OR-8.
 43. Barnes MM, Dorsch MP, Kim S, Aaronson K, Koelling T, Bleske BE. Baseline albumin predicts worsening renal function in acute decompensated heart failure patients receiving continuous infusion loop diuretics. American College of Clinical Pharmacy 2012 Annual Meeting, Hollywood, Florida. *Pharmacotherapy* 2012;32:e187.
 44. Dorsch MP, Barnes MM, Wu AH, Bleske BE. The effect of continuous infusion loop diuretics in acute decompensated heart failure patients with hypoalbuminemia. American College of Clinical Pharmacy 2012 Annual Meeting, Hollywood, Florida. *Pharmacotherapy* 2012;32:e188.
 45. Bleske BE, Remington T, Wells T, Dorsch M, Guthrie S, Stumpf J, Alaniz M, Eliingrod V, Tingen J. Comparing team-based learning to lecture on learning outcomes in a therapeutics course. Team Based Learning Collaborative Annual Meeting, San Diego, CA, March 1, 2013.
 46. Diez HL, Remington T, Mason N, Tingen J, Wells T, Ramaswamy V, Carver P, Bleske BE, Ellingrod VL. Pharmacy students performance comparing team based learning and a traditional didactic pedagogy. Team Based Learning Collaborative Annual Meeting, San Diego, CA, March 1, 2013.
 47. Bleske BE, Cornelius D, Ward JK, Pickworth KK, Bennett MS, Diez HL, Dorsch MP, Nicklas JM. Heart Failure Assessment at the Community Pharmacy Level –A Feasibility Pilot Study. Heart Failure Society of

- American Annual Meeting, Sept 22-25, 2013, Orlando, Florida. *Journal of Cardiac Failure* 2013;19 (8S):S44 (126).
48. Dorsch MP, Farris KB, Bleske BE, Koelling TM. A web application for self-monitoring improves symptoms in chronic heart failure. *Annals of Behavioral Medicine*. April 2014; 14 (1) Supp: s106.
 49. Pressler SJ, Titler M, Koelling T, Riley P, Jung M, Domenico L, Ronis D, Smith D, Bleske B, Giordani B. Cognitive training to improve memory in heart failure: A randomized controlled study. Paper presentation at the Midwest Nursing Research Society 38th Annual Research Conference. Indianapolis, IN, April. 2015
 50. Titler M, Jung M, Pressler SJ, Koelling T, Riley P, Domenico L, Ronis D, Smith D, Bleske B, Giordani B. Balance correlates with global cognition and processing speed in heart failure. Paper presentation at the Midwest Nursing Research Society 38th Annual Research Conference. Indianapolis, IN, April. 2015
 51. Koenigsnecht MJ, Fioritto AF, Baker JR, Bleske B, Young VB, Hasler WL, Sun D. Novel technique for gastrointestinal fluid isolation and microbiome analysis following administration of different mesalamine formulations in healthy volunteers. *Digestive Disease Week® (DDW) 2015*. May 16 – May 19, 2015 at the Walter E. Washington Convention Center in Washington, DC.
 52. Fioritto AF, Baker JR, Collins K, Wen B, Wang Y, L Ruijuan, Bleske BE, Johnson M, Koenigsnecht M, Hasler WL, Sun D. Contrasting regional availability of different mesalamine products in the gastrointestinal tract in healthy humans using a novel multi-port luminal aspiration system and correlation with systemic absorption. *Digestive Disease Week® (DDW) 2015*. May 16 – May 19, 2015 at the Walter E. Washington Convention Center in Washington, DC.
 53. Jung M, Titler M, Riley P, Bleske B, Pressler SJ. A New Measure of Healthcare Resource Utilization in Heart Failure: Development and Content Validity Evaluation. *Heart Failure Society 19th Annual Scientific Meeting*, September 26-30, 2015, Washington D.C.
 54. Mahmood SM, Al-Babtain M, Brenner M, Bleske BE. Effect of hyponatremia in heart failure patients on cognitive function and mobility. *ASHP Midyear Meeting Student Presentation*, December 6, 2015, New Orleans, LA.
 55. Koenigsnecht MJ, Fioritto AF, Baker JR, Tsume Y, Wen B, Zhao T, Dickens J, Wysocki J, Shedden K, Bleske B, Hasler WL, Amidon GL, Sun D. Regional In Vivo Dissolution of Immediate Release Ibuprofen in Human Gastrointestinal Tract and Its Relationship to Luminal pH and Systemic Absorption. *Digestive Disease Week® (DDW) 2016*. May 21 – May 24, 2016, San Diego, CA.
 56. Fioritto AF, Yu A, Baker JR, Collins K, Wen B, Wang Y, Luo R, Li S, Bleske B, Johnson M, Koenigsnecht M, Ph.D., Hasler WL, Sun D. Direct Comparison of In Vivo Drug Release Profiles of Three Locally-Acting Drug Products of Mesalamine in the Gastrointestinal Tract and Correlation With Systemic Exposure and Fecal Concentrations in Healthy Humans. *Digestive Disease Week® (DDW) 2016*. May 21 – May 24, 2016, San Diego, CA.
 57. Goff ZD, Vidic A, Chibnall JT, Bleske B, Hauptman PJ. Variability in Pricing of Generic Drugs for Heart Failure: Caveat Emptor. *American Heart Association Scientific Session*, Nov 15, 2016, New Orleans, LA.
 58. Bermejo M, Tsume Y, Paixao P, Koenigsnecht MJ, Hens B, Baker JR, Frances A, Wen B, Zhao T, Dickens J, Yu A, Pai M, Bleske B, Wysocki J, Shedden K, Lee A, Hasler WL, Sun D, Amidon GL. Gastrointestinal Motility and Luminal pH Influence *In Vivo* Dissolution and Systemic Absorption of Drug Product in Human Gastrointestinal Tract Under Fed and Fasted Conditions. *European Society for Neurogastroenterology and Motility meeting*. Cork, Ireland, 2017
 59. Takeda, M. Y, Wittstrom, K. M., Bleske, B. E. Education of Complementary and Alternative Medicine in Pharmacy Curriculum," *American Association of Colleges of Pharmacy*, Gaylord Opryland Resort & Convention Center, Nashville, TN, United States. (July 16, 2017)
 60. Bleske BE, Zhu HJ, Hanley-Yanez K, Halder I, McNamara DM. NAT2 genotype and outcomes in the Genetic Sub-Study of the African American Heart Failure Trial (AHeFT). *American Heart Association Scientific Session*, November 11, 2017, Anaheim, California. *Circulation*. 2017;136:A15213.
 61. Bermejo M, Tsume Y, Paixao P, Koenigsnecht MJ, Hens B, Baker JR, Frances A, Wen B, Zhao T, Dickens J, Yu A, Pai M, Bleske B, Wysocki J, Shedden K, Lee A, Hasler WL, Sun D, Amidon GL. (2017) Linking Gastrointestinal In Vivo Dissolution and Ibuprofen Systemic Absorption. *American Association of Pharmaceutical Scientists (AAPS) 2017 San, Diego CA*.
 62. Yamada-Takeda M, Naloxone study - a gap between students' perception and ability in opioid overdose education and naloxone use. *American Association of Colleges of Pharmacy Annual Meeting*, July 22, 2018, Boston, MA.
 63. J. Begay, Y. Ordonez, S. Lucas, B. Sanchez, A. Wheeler, F. Baldwin Jr., G. Herbert, C. Shuey, J. Harkema, J. Wagner, M. Morishita, B. Bleske, and M. Campen. P117: In Vivo Toxicity Assessment of Metal

Contaminated Wind Blown Particulate Matter from an Abandoned Uranium Mine on the Navajo Reservation. Society of Toxicology, March 2019, Baltimore, MD.

64. J. Tworek, B. Sanchez, F. Baldwin, A. Wheeler, G. Herbert, S. Lucas, M. Morishita, B. Bleske, M. Campen, M. Paffett, and K. Zychowski. Effects from Airborne Metal-Enriched Particulate Matter from an Abandoned Uranium Mine. Society of Toxicology, March 2019, Baltimore, MD.
65. J. Begay; B. Sanchez; A. Wheeler; F. Baldwin, Jr.; S. Lucas; G. Herbert; Y. Ordonez; C. Shuey; J. Harkema; J. Wagner; M. Morishita; B. Bleske; M. Campen. Using the Mobile Air Research Lab to for in vivo assessment of Metal Contaminated Wind-Blown Particulates from Abandoned Uranium Mines within U.S. American Indian Tribal Lands. 13th International Particle Toxicity Conference, Salzburg, Austria, Sept 12, 2019

GRANT/RESEARCH ACTIVITY – PI or Co-PI (External and Internal Funding)

1. "Comparison of the effect of immediate and sustained release verapamil on propranolol pharmacokinetics," Rackham Faculty Grant, University of Michigan. Approved and funded; \$10,000; 1/90-10/92.
2. "The effect of epinephrine (nasal) on survival post CPR," Upjohn Research Endowment Fund, College of Pharmacy, The University of Michigan. Approved and funded; \$25,000; 2/90-6/91.
3. "Effect of SR and IR verapamil on quinidine pharmacokinetics," Astra Sixth Annual Clinical Pharmacy Research Award, honorable mention (not funded), 1990.
4. "The influence of H2-antagonists on cardiac function," Roche Pharmaceuticals. Funded; \$12,000; PI, 10/90. 5% salary support
5. "The influence of dosage form on the pharmacokinetics and pharmacodynamics of propranolol enantiomers," Michigan Clinical Research Center. Approved and funded; 4/91.
6. "The effect of sodium bicarbonate administration on the vasopressor effects of high dose epinephrine during cardiopulmonary resuscitation in swine," ACCP-Glaxo Pharmacotherapy Research Award. Approved and funded; PI \$5,000; 7/91-7/92.
7. "Evaluation of prothrombin time variability over a 24-hour period," Michigan Clinical Research Center. Approved and funded; 1/92.
8. "The effect of dose and vehicle on the nasal absorption of epinephrine during CPR," American Heart Association. Approved and funded; \$19,000; PI, 7/93 - 6/94. 5% salary support.
9. "Effect of Dosage Release Formulations on Drug Clearance," Astra Ninth Annual Clinical Pharmacy Research Award, honorable mention (not funded), 1993.
10. "Evaluation of ACE-Inhibitor Therapy for Heart Failure," Merck Pharmaceutical. Funded; \$19,113, PI; 1/94 - 12/95. 10% salary support.
11. "Pharmacokinetics and pharmacodynamics of oral demadex in compensated and decompensated patients with congestive heart failure. Boehringer Mannheim. Funded; \$79,704;5/95-11/95 (Co- PI, 5% salary support).
12. "The effect of HMG-CoA Reductase Inhibitors on Coenzyme Q10. Bristol Myers Squibb, Funded \$14,500.00 - PI. 12/98 – 12/99.
13. "The effect of atorvastatin beyond lipid lowering: The effect of atorvastatin on endothelial function and TNF in heart failure." Pfizer Inc. Funded \$110,875.00, 1/1/02 – 12/31/02, 5% salary support
14. "Atorvastatin and biochemical markers". Pfizer Inc. Funded \$57,500.00 - PI. 1/1/2002 to 1/31/2003.
15. "The Effect of Digoxin on Myocyte Contractility in the Presence of Pravastatin or Lovastatin. The Role of P-glycoprotein and HMG-CoA Reductase Inhibitors". Bristol Myers Squibb, funded, \$5,000.00 - PI 12/01/01 – 12/01/02.
16. "The Effect of Rosuvastatin on Extracellular Matrix Components in an Aortic Constriction Model". Astra-Zeneca, funded, \$119,544.00 - PI. 09/01/03 – 08/30/04, 5% salary support.
17. "Mechanisms of Hawthorn Action in Heart Failure" NIH R21 AT002192-01, \$356,812.00 - PI. 09/15/04 – 07/31/06, 15% salary support.
18. "The Effect of Paroxetine and Sildenafil on the Pharmacokinetics of Metoprolol and Carvedilol". Astra-Zeneca. Funded \$526,834.00 - PI. 05/01/05 – 04/30/08, 10% Salary support.
19. "Role of Vitamin D in Heart Failure" CTSA, \$5,000 - PI. 10/01/08 – 10/01/12.
20. "Heart Failure One Minute Clinic" – Funded \$16,149.00 – PI, Community Research Foundation. 11/01/11 to 10/30/13, 2.5% salary support.

21. “Tolvaptan in High Risk HF Patients” – \$64,596.00 - PI, Funded Otsuka Pharmaceuticals 01/12 – 06/13, 10% salary support.
22. “My (MI) Heart Mobile App” – Foster Innovation Grant, University of Michigan Health Systems, \$10,000. 06/01/12 – 10/31/14.
23. “A Randomized Comparison between Team Based Learning and Standard Lecture Format on Learning Outcomes” \$3,000.00. Investigating Student Learning Grant, Center for Research on Learning and Teaching University of Michigan. 03/14-09/15.
24. “A Virtual Translational Step from Class Room to Real World. \$25,000.00. Third Century Funding. Quick Wins, University of Michigan. Co-PI with V. Ellignrod Pharm.D. and T. Remington, Pharm. D.
25. “The Effect of Hyponatremia in Heart Failure Patients on Driving Ability, Cognitive Function, and Gait.” Approved Otsuka Pharmaceuticals \$186,000.00 – PI. Initially approved by Otsuka (10/14) but funding was retracted due to a shift in company priorities.
26. “WS 1442 Regulation of eNOS Expression via Epigenetic Mechanisms – Focus on MicroRNAs. Funded \$48,267 - PI Schwabe Pharmaceuticals. Salary support (15-PAF03258). 2013-2015.
27. Student Perception and Confidence regarding Naloxone prescribing. SOLT UNM College of Pharmacy. 2017.
28. “Pharmacy-based Population Health Model for the Detection of Silent Atrial Fibrillation”. Funded \$125,822. PI - Bristol-Myer Squibb Foundation for Global Medical Impact. Salary Support. 10/17 – 03/19.
29. “Community Pharmacy Practice Innovation through Curricular Initiatives” Funded \$20,000. PI - NACDS

GRANT/RESEARCH ACTIVITY – Co-Investigator with salary support (recent)

1. “Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients.” Gilead Science, Inc. \$120,000.00. 04/18/2012 to 07/31/2013. B. Mueller, Pharm. D., PI (Salary Support)
2. “Correlation of Mesalamine Pharmacokinetics with Local Availability, Clinical Trial”. Health and Human Services, Department of Food and Drug Administration. \$500,000. 09/13/13 – 09/12/15. D. Sun, Ph.D., PI (5% Salary Support)
3. “Modernization of in vivo-in vitro Oral Bioperformance Prediction and Assessment”. Health and Human Services, Department of Food and Drug Administration. \$500,000. 09/13/13 – 09/12/15. D. Sun, Ph.D., PI (5% Salary Support)
4. CES1 variants as determinant of ACEI activation: a healthy volunteer study.” 1R21 AG048500-01. \$275,000 direct cost. (5% salary support) H. Zhu, Ph.D., PI. Project Period 2015-2017.
5. “Genetic determinants of ACEI prodrug activation.” 1R01HL126969-01A1. Project Period 09/01/2015 - 08/31/2020. Total budget: \$1,948,750.00. (10% salary support) H. Zhu, Ph.D., PI.

III. PROFESSIONAL ACTIVITIES – RESEARCH & CLINICAL RELATED

A. Reviewer

1992	Abstract Reviewer, ACCP 13th Annual Meeting
1993	Abstract Reviewer, ACCP 14th Annual Meeting
1994	Abstract Reviewer, ACCP 15th Annual Meeting
1994-2006	U of M General Clinical Research Center - Protocol Reviewer
1994	ACCP - Pharmacotherapy Self-Assessment Program Reviewer for CPR.
1995	Abstract Reviewer ACCP 16th Annual Meeting
1996	Abstract Reviewer ACCP Winter Practice and Research Forum
1996	Abstract Reviewer ACCP 17th Annual Meeting
1996-2000	Journal Reviewer - Biopharmaceutics & Drug Disposition
1996-Present	Journal Reviewer - Pharmacotherapy
1997-2000	Journal Reviewer - Hospital Pharmacy
1998	Abstract Reviewer ACCP Spring Practice and Research Forum
1998	Journal Reviewer - Journal of Clinical Pharmacology
1999	Abstract Reviewer International Congress on Clinical Pharmacy
1999	Abstract Reviewer ACCP 20 th Annual Meeting

2000 Abstract Reviewer ACCP Spring Practice and Research Forum
 2000 Astra-Zeneca Clinical Pharmacy Research Award
 2001 ACCP Pharmacotherapy Research Award
 2001 Abstract Reviewer ACCP Spring Practice and Research Forum
 2001 ACCP – Pharmacotherapy Self-Assessment Program Reviewer for CPR.
 2001 Abstract Reviewer ACCP Annual Meeting
 2002 Abstract Reviewer ACCP Annual Meeting
 2002 Abstract Award Reviewer ACCP Annual Meeting
 2003 Journal Reviewer – JAMA
 2004 Abstract Reviewer ACCP Annual Meeting
 2004 Abstract Review ACCP Spring Meeting 2005
 2005 Abstract Reviewer – ACCP Annual Meeting
 2004 Journal Reviewer - Current Topics in Nutraceutical Research
 2005 Abstract Reviewer – ACCP Spring Meeting 2006
 2006 Journal Reviewer – European Journal of Clinical Investigation
 2006 Abstract Reviewer – ACCP Fall Meeting 2006
 2007 Abstract Reviewer – ACCP Spring Meeting 2007
 2007 Abstract Reviewer – ACCP Fall Meeting 2007
 2008 Journal Reviewer – Coronary Artery Disease
 2008 Journal Reviewer – European Journal of Cardiology
 2008 Abstract Reviewer – ACCP Fall Meeting 2008
 2009 Abstract Reviewer – ACCP Spring Meeting 2009
 2009 Abstract Reviewer – ACCP Fall Meeting 2009
 2009 Journal Reviewer – Planta Medica
 2010 Journal Reviewer – American Journal of Cardiology
 2010-Present Journal Reviewer – Journal of Cardiac Failure
 2011 Abstract Reviewer – ACCP Annual Meeting 2011
 2012 Journal Reviewer – American Journal of Cardiology
 2012 Abstract Reviewer – ACCP Annual Meeting 2012
 2012 ACCP - Pharmacotherapy Self-Assessment Program Reviewer for HFpEF
 2012 American College of Cardiology - Michigan Chapter – Poster Judge
 2013 Abstract Reviewer – ACCP Annual Meeting 2013
 2013-Present Journal Reviewer – American Journal of Pharmaceutical Education
 2014 Journal Reviewer – Telemedicine and e-Health
 2015 Abstract Reviewer – ACCP Global Conference
 2016 Abstract Reviewer – American Heart Association
 2016 Abstract Reviewer – HFSA
 2016 Abstract Reviewer – ACCP
 2017 Abstract Reviewer – Virtual Session ACCP.
 2017 Abstract Reviewer – HFSA
 2017 ACCP - PSAP Reviewer for Acute Heart Failure
 2018 Abstract Reviewer –HFSA
 2019 Abstract Reviewer - ACCP

B. Review Section

1994-2006 U of M General Clinical Research Center – Research Protocol Reviewer
 2014 Veterans Health Administration Epidemiology (EPID) Review Panel, Washington D.C.
 2015-Present UNM CTSA Pilot Award
 2019 AHA review on USPSTF statement on Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer

C. Invited Lecture - International/National/State/Local (Selected Sample)

1. Drug Interactions and Pharmacokinetics of Oral Contraceptives. Presented to nurse practitioners at Planned Parenthood of Minnesota, 1985.
2. Drugs and Renal Failure. Presented to Dialysis Unit, Hennepin County Medical Center, Minneapolis, Minnesota, 1985.
3. Osmotic agents and furosemide in the treatment of increased intracranial pressure. Presented to Department of Neurosurgery, St. Paul Ramsey Medical Center, St. Paul Minnesota, 1985.
4. Cardiotonic and Vasoactive Agents. Presented to flight nursing students, Hartford Hospital, Hartford, Connecticut, 1986.
5. Hypertension. Pharmacy Conference, Hartford Hospital, Hartford, Connecticut, 1987.
6. Amiodarone electrophysiological experience. Cardiology Conference, Hartford Hospital, Hartford, Connecticut, 1987.
7. Antiarrhythmic Agents. Cardiology Conference, Day-Kimball Hospital, Connecticut, 1987.
8. Calcium Channel Blockers in the Treatment of Hypertension. Presented at the Vermont Pharmacists Association Annual Meeting, 1987.
9. Antiarrhythmic Agents. Presented at Pharmacy Conference, Hartford Hospital, Hartford, Connecticut, 1988.
10. Cardiac Medications, Ann Arbor Heartbeats Club, Ann Arbor, Michigan, February 1990.
11. Aspirin and the Heart, 13th Annual Pharmacy Practice Institute, Albany College of Pharmacy, Albany, New York, February 1991.
12. Angiotensin Converting Enzyme Inhibitors, 13th Annual Pharmacy Practice Institute, Albany College of Pharmacy, Albany, New York, February 1991.
13. The Effect of Intranasal Epinephrine During CPR, Alumni Society Board of Governors Meeting, University of Michigan, College of Pharmacy, Ann Arbor, Michigan, April 1991.
14. The Use of Epinephrine and Sodium Bicarbonate During CPR, Pharmacy Research Conference, University of Michigan, College of Pharmacy, Ann Arbor, Michigan, October 1992.
15. Clinical Features and Consequences of Heart Failure, for the symposium on Pharmacologic Principles and Drug Selection in the Prevention and Management of Heart Failure, Orlando, Florida, December, 1992. Sponsored by Boots Pharmaceuticals.
16. ACLS Update and Case Studies in Cardiac Arrest. Presented at the Annual Midwinter Meeting for the New Mexico Society of Hospital Pharmacists, Farmington, New Mexico, February, 1993.
17. Controversies in ACLS. University of Michigan, College of Pharmacy 15th Annual Spring Seminar, Ann Arbor, Michigan, April, 1993.
18. Management of Congestive Heart Failure. Presented as a teleconference for the Teleconference Network of Texas, April, 1993.
19. Circadian Variation. Lecture presented at The University of Michigan, General Clinical Research Center Seminar Series. August, 1993.
20. Updates and Controversies in ACLS. Lecture presented at The University of Manitoba and University of Saskatchewan, March, 1994.
21. CPR and Survival: Focus on Drug Therapy and Coronary Perfusion Pressure. Research lecture presented at The University of Manitoba and University of Saskatchewan, March, 1994.
22. Endothelial Factors in Angina: The Clinical Implications. Atwood, Michigan, July 1994.
23. Nitrate Therapy in Angina. Presented to Western Michigan Society of Hospital Pharmacists. Bronson Hospital, Kalamazoo, Michigan, November 16, 1994.
24. Congestive Heart Failure - Presented to Northern Michigan Society of Hospital Pharmacists. Gaylord, Michigan, March 8, 1995.
25. Chronobiology - Presented at Managed Care Conference. San Francisco, California, May 10, 1996.
26. Chronobiology - Focus on Cardiovascular Therapy - Presented at Grand Rounds, Crittenton Hospital. Rochester, Michigan, May 21, 1996.
27. New Concept for Pharmacotherapy - Chronotherapeutics - Presented at the Minnesota Pharmacists Association Meeting. Minneapolis, Minnesota, September 22, 1996.
28. Update in Heart Failure. Presented at the Toledo's Academy of Pharmacy Meeting, Toledo, Ohio, September 18, 1997.
29. Cytochrome P-450 and Drug Interactions - Presented at Washington State University CE Program, Couer d' Alene, ID, March 13, 1998.

30. Beta-blockers and Heart Failure. Presented at the Western Michigan Society of Hospital Pharmacists Spring Meeting, Grand Rapids, MI, May 6, 1998.
31. Current Treatment Approaches: The role of IV vasodilators and inotropes. Presented at the 1998 Midyear Clinical Meeting in Las Vegas, Nevada, December 7, 1998.
32. Calcium channel blockers increase the risk for acute myocardial infarction? – Debate at the 1998 Midyear Clinical Meeting in Las Vegas, Nevada, December 9, 1998.
33. Update in Heart Failure. Presented at Wishard Hospital, Indianapolis, IN, October 13, 1999.
34. New pharmacological strategies in the management of hypertension and cardiac failure. Presented at the 1999 Midyear Clinical Meeting in Orlando, Florida, December 7, 1999
35. Pathophysiology of systolic heart failure – Presented at the 2000 Spring Practice and Research Forum of the American College of Clinical Pharmacy, April 2, 2000, Monterey, California.
36. Are All Beta-Blockers the Same? Presented at the Cardiology Regional Advisory Board Meeting – AstraZeneca, July 23, 2000, Dearborn, Michigan
37. Approach to Drug Interactions: Presented to Family Practice Physicians – Port Austin, MI, August 21, 2000.
38. Inhibition of the SNS – Beta Blockers and Heart Failure. Presented at the 2000 Midyear Clinical Meeting in Las Vegas, NV, December 4, 2000.
39. Case Studies in Heart Failure. Presented at the Michigan Pharmacists Association Annual Meeting, February 17, 2001, Dearborn, Michigan.
40. The Clinical Spectrum of Beta-Blockade: The Distinct Advantages. Presented at the 2001 Midyear Clinical Meeting in New Orleans, LA, December 3, 2001
41. Heart Failure – Bedside to the Bench. Presented at the University of Montana College of Pharmacy, February 1, 2002, Missoula, MT.
42. Treatment of Acute Heart Failure. Presented at American Pharmaceutical Association Annual Meeting, March 16, 2002, Philadelphia, PA.
43. Treatment of Heart Failure. Presented to Family Practitioners and General Internists, April 22, 2002, Troy, MI.
44. Beta Blockers as Part of the New Standard of Care in Heart Failure. Grand Rounds, Genesis Medical Center,, September 18, 2002, Davenport, IA.
45. Beta Blockers in the Treatment of Heart Failure. Grand Rounds, Pontiac Osteopathic Hospital, October 30, 2002, Pontiac, MI.
46. Disease Interrupted: Beta blockers in Heart Failure. Grand Rounds, Metro West Medical Center, November 19, 2002, Framingham, MA.
47. Heart Failure: Lima Medical Society, Lima, Ohio. March 18, 2003.
48. Treatment of Advanced Heart Failure. Macomb Pharmacists Association. Roseville, MI March 26, 2003.
49. Beta Blockers and Heart Failure. Northern Michigan Pharmacists Association. Gaylord, Michigan. April 17, 2003.
50. Neurohormonal Antagonists. Managed Care Pharmacists. Southfield, Michigan. May 14, 2003.
51. Update in Hypertension and Lipid Guidelines. Toledo College of Pharmacy. Toledo, Ohio, December 1, 2003.
52. New Lipid Therapies. Monroe Medical Society, Monroe, MI, December 2, 2003.
53. Update on Lipid Therapy. Washtenaw County Pharmacists Association, Ann Arbor, MI, March 4, 2004.
54. Comparison Among the Statins. Cardiology Department, Henry Ford Hospital, Detroit, MI, May 17, 2004.
55. Cardiovascular Drug Interactions – Cardiology Update – Mackinaw Island, MI, August 20-22, 2004.
56. Common Sense Approaches to Cardiovascular Drug Metabolism & Interactions. 26th Annual Cardiology Update, Ingham Regional Medical Center, East Lansing, MI, October 8, 2004.
57. Case-Based Approach to Cardiovascular Problems. 27th Annual Cardiology Update, Ingham Regional Medical Center, East Lansing, MI, October 7, 2005.
58. Getting to LDL Goal. NP Meeting, Birmingham, MI, December 8, 2005.
59. Heart Failure Update 2010. American College of Clinical Pharmacy 2005 Annual Meeting. San Francisco, CA, October 22, 2005.

60. Heart Failure in Specialized Populations. American Pharmacists Association 2006 Annual Meeting. San Francisco CA, March 19, 2006.
61. Protocol Development – Research Proposal Writing Workshop, Kalamoon University, Syria, May 5, 2007.
62. Developing Budgets and Identifying Funding Opportunities - Research Proposal Writing Workshop, Kalamoon University, Syria, May 6, 2007.
63. Dissemination of Information. Research Proposal Writing Workshop, Kalamoon University, Syria, May 7, 2007.
64. Role of Heart Failure Team – Case Approach. Heart Failure Management Conference, Amelia Island, Florida, July 15, 2007
65. Cardiovascular Update. University of Michigan Annual Pharmacy Lectures, Ann Arbor, MI, October, 2007.
66. CV Drug Interactions. Update in Office Cardiology. The Inn at St. John’s, Plymouth, MI November 10, 2007.
67. A Tenure Track Faculty Perspective on Teaching Clinical Pharmacy. The International Conference on Pharmacy Education and Practice. Damascus, Syria, November 2, 2007.
68. CV Medications and the Kidney. Update in Cardiovascular Nursing. Advance Practice Nurses. Washtenaw Community College, Ann Arbor, Michigan, March 3, 2008.
69. Pharmacotherapeutic Challenges in Treating the Heart Failure Patient. Heart Failure Management Conference, Amelia Island, Florida, July 19, 2008
70. Team Approach to Managing Co-morbidities in CHF Clinic. Focus on Anemia, Diabetes, and Renal Insufficiency. Heart Failure Management Conference, Amelia Island, Florida, July 20, 2008
71. Clinical Applications of a Nitric Oxide Sensor. Invited Presentation Biomarin Pharmaceuticals, Novato, California, July 2008.
72. New Directions: Hawthorn for Heart Failure & Bedside Nitric Oxide Sensor for Drug Monitoring. Midwest College of Clinical Pharmacy Meeting, Omaha, Nebraska, September 25, 2008.
73. Next Step Hawthorn and Heart Failure. Invited Presentation - Schwabe Pharmaceuticals. Karlsruhe, Germany, October 20, 2008.
74. Global Cardiovascular Risk. Doshisha Women’s College, Kyoto, Japan, May 13, 2009.
75. Pharmacotherapeutic Challenges in Treating the Heart Failure Patient. Heart Failure Management Conference, Amelia Island, Florida, July 18, 2009.
76. Team Approach to Managing Co-morbidities in CHF Clinic. Heart Failure Management Conference, Amelia Island, Florida, July 19, 2009.
77. Vitamin D and CVD. Abbott MSL Regional Meeting, Chicago, Illinois, August 12, 2009.
78. The Sunshine Effect: Micronutrients in Cardiovascular Disease. Cardiology Update, Mackinaw Island, MI, August 21-23, 2009.
79. Office Pharmacogenomics and Biomarkers. Cardiology Update, Mackinaw Island, MI, August 21-23, 2009.
80. Practical Approaches to Common CV Drug Interactions. Cardiology Update, Mackinaw Island, MI, August 21-23, 2009.
81. Common CAMS – Evidence Base? 33rd Annual Midwinter Family Practice Update, Boyne Highlands, Harbor Springs, MI, Feb 1-5, 2010.
82. Common CV Interactions. 33rd Annual Midwinter Family Practice Update, Boyne Highlands, Harbor Springs, MI, Feb 1-5, 2010.
83. Micronutrients/Supplements and CV disease. 33rd Annual Midwinter Family Practice Update, Boyne Highlands, Harbor Springs, MI, Feb 1-5, 2010.
84. Treating the Heart Failure Patient. Heart Failure Management Conference, Amelia Island, Florida, July, 2010.
85. Case Studies in Treating Heart Failure Patients. Heart Failure Management Conference, Amelia Island, Florida, July 2011.
86. Alternative Medicines and Cardiovascular Disease. Take Heart Conference – Update in Cardiovascular Nursing. Ann Arbor, Michigan, March 5, 2012.
87. Medication Adherence in Heart Failure Patients. Heart Failure Management Conference, Amelia Island, Florida, July 2012.

88. Prevention and Management of Statin Induced Myopathy. American Heart Association Scientific Session (CVS.201), Los Angeles, California, Nov 3, 2012
89. Pharmacotherapeutic Challenges in Heart Failure Patients. Take Heart Conference – Update in Cardiovascular Nursing. – Ann Arbor, Michigan, March 4, 2013.
90. Nasal Administration of Epinephrine during CPR – The Beginning. – Invited presentation to Shin Nippon Biomedical Laboratories, Tokyo, Japan, May 9, 2013.
91. Pharmacotherapeutic Challenges. Heart Failure Management Conference, Amelia Island, Florida, July 2012.
92. Team Based Learning and Your Curriculum. Invited presentation – Wayne State University College of Pharmacy, Detroit, Michigan, July 10, 2013
93. Prevention and Management of Statin-Induced Myopathy. Heart Failure Management Conference, Amelia Island, Florida. July 2013.
94. Recommendations to Reduce the Problem – You and Your Patient and OTC’s and CAMS. Heart Failure Society of American 17th Annual Meeting. Orlando, Florida, September 24, 2013.
95. Cardiac Medications and Interactions with Herbals and CAM. Take Heart Conference – Update in Cardiovascular Nursing. – Ann Arbor, Michigan, March 3, 2014
96. Making Patient Centered Decisions about Medications. Heart Failure Management Conference, Amelia Island Florida, July 2014.
97. Putting it All Together How Do Clinical Pharmacists Integrate into the Clinical Trials Process. ACCP Annual Meeting – Austin, Texas, October 14, 2014.
98. Lessons from the Trenches – Team Based Learning. Concordia College, Mequon, WI, February 26, 2015.
99. Wine, Chocolate, and Yoga. Therapeutic Lifestyle Interventions. Take Heart Conference – Update in Cardiovascular Nursing. – Ann Arbor, Michigan, March 2, 2015.
100. Improving Medication Adherence in HF. Heart Failure Management Conference, Amelia Island, Florida, July 2015.
101. Nutraceuticals: Hawthorn, Co-enzyme Q10, Omega-3’s. Heart Failure Society of America 19th Annual Program, National Harbor, Maryland, September 28, 2015.
102. Crataegus Oxycantha to Team-Based Learning. Pharmaceutical Science Seminar, University of New Mexico, College of Pharmacy. October 5, 2015
103. PL Voices Clinical Webinar Series: Clinical Recommendations – Managing Heart Failure During Transitions of Care. January 19, 2016.
104. Navigating the Contemporary Medication Armamentarium. Heart Failure Management Conference, Amelia Island, Florida, July 2016.
105. Clinical Pearls in HF Management. Heart Failure Management Conference, Amelia Island, Florida, July 2016.
106. Team Based Learning. University of Kumamoto, Kumamoto Japan, October, 2016.
107. Expanding the Heart Failure Toolbox: Patient Assessments. ASHP Midyear Meeting, Las Vegas, NV, December 6, 2016.
108. Workshop – Team Based Learning Pedagogy – What it is, Pearls, and Outcomes. Dubai International Pharmaceuticals and Technologies Conference and Exhibition. Dubai, UAE, March 8, 2017.
109. Heart Failure Assessment at the Community Pharmacy Level – Pharmacy Curriculum and Practice Advancement. Dubai International Pharmaceuticals and Technologies Conference and Exhibition. Dubai, UAE, March 9, 2017.
110. Managing Multiple Medications in Heart Failure. CE webinar presentation – Postgraduate Healthcare Education. March 23, 2017.
111. Optimizing Care of Patients with Heart Failure. CE webinar presentation – Postgraduate Healthcare Education. March 30, 2017.
112. Pharmacotherapeutic Challenges in Managing Heart Failure and Common Comorbidities. Heart Failure Management Conference, Amelia Island, Florida, July 2017.
113. Clinical Pearls in HF Management. Heart Failure Management Conference, Amelia Island, Florida, July 2017.

114. Management of Atrial Fibrillation. Preceptor CE webinar. University of New Mexico, College of Pharmacy, January 16, 2018.
115. Chronic Non-Valvular Atrial Fibrillation & A Pharmacy-based Population Health Model for Detection of Atrial Fibrillation NMPHA Annual Convention 2019
116. Pharmacotherapeutic Challenges in Managing Heart Failure and Common Comorbidities. Heart Failure Management Conference, Amelia Island, Florida, July 2018.
117. Curricular Driven Health Model for Detection of Atrial Fibrillation. Global Education Seminar on Pharmacy and Pharmaceutical Sciences. Nagasaki University, Nagasaki, Japan, March 7, 2019.
118. Pharmacotherapeutic Challenges in Managing Heart Failure and Common Comorbidities. Heart Failure Management Conference, Amelia Island, Florida, July 2019.

D. Organizing Meetings, Symposia, Moderator

- | | |
|------|--|
| 1993 | Cardiology Program Chairman, Research Methods in Cardiology, 1993 ACCP Winter Practice and Research Meeting |
| 1993 | Course Director - Newer guidelines for therapy in cardiovascular medicine. Michigan State Medical Society, 1993 Annual Scientific Meeting, November, 1993, Detroit, Michigan |
| 1994 | Program Committee for 1995 ACCP Annual Meeting, Washington D.C. |
| 1995 | Moderator, Cardiology Focus Session, 1995 ACCP Annual Meeting, Washington D. C. |
| 1995 | Program Committee for 1996 ACCP Annual Meeting, Nashville, Tennessee. |
| 1999 | Program Committee for 2000 ACCP Meeting, Spring Forum. |
| 2000 | Moderator, ACCP Scientific Series "Finding and Acquiring Research Funding" 2000 Spring Practice and Research Forum, Monterey, California. |
| 2007 | Moderator, Advances in Complementary and Alternative Medicine: Focus on Chronic Diseases. 2007 ACCP Annual Meeting, Denver, Colorado, October 2007. |
| 2012 | Program Committee – Take Heart – Update in Cardiovascular Nursing, March 5, 2012, Ypsilanti, MI. |
| 2013 | Program Committee – Take Heart – Update in Cardiovascular Nursing, March 4, 2013, Ann Arbor, MI. |
| 2014 | Program Committee – Take Heart – Update in Cardiovascular Nursing, March 3, 2014, Ann Arbor, MI. |
| 2015 | Program Committee – Take Heart – Update in Cardiovascular Nursing March 2, 2015, Ann Arbor, MI |

E. Consultantships

- | | |
|-----------|---|
| 1992-1993 | Boots Pharmaceutical Pharmacy Advisory Board |
| 1996-1997 | Searle, Chiralscience Advisory Board |
| 1998 | Bayer Pharmaceutical Advisory Board |
| 2000-2005 | AstraZeneca National Consultant – Heart Failure |
| 2001 | Scios Advisory Board |
| 2003 | BMS Advisory Board |
| 2004-2010 | Rosuvastatin National Consultant |
| 2004-2006 | Abbott National Consultant |
| 2006-2009 | ARCA Advisory Board |
| 2009-2010 | Eli Lilly Speakers Bureau |
| 2011-2012 | Novartis HF National Advisory Board |
| 2012-2014 | Otsuka Speakers Bureau |

IV. Other Professional Activities and Recognition

A. Expert witness/consultant

- | | |
|------|-------------------------------|
| 1989 | Nunneley, Hirt & Rinehart |
| 2000 | Smith, Haughey, Rice & Roegge |

2003 Sidley, Austin, Brown, & Wood
2006 United States Attorney General's Office
2011 United States Attorney General's Office

B. Professional society membership and other

1988-Present American College of Clinical Pharmacy
1991-Present American Heart Association
1997-2000 Wayne State University Board of Governors
1999-Present Heart Failure Society of America

C. Appointments to committees

1993 Research Affairs Committee - ACCP
1994 Program Committee - ACCP
1995 Program Committee - ACCP
1998 Chair, Awards Committee - ACCP
1999 Program Committee, Abstract Chair – ACCP
1999 Fellowship Committee – ACCP
2000-2013 Cardiology PRN – Young Investigator/Resident Poster Committee
2015-Present Digital Committee – Heart Failure Society of America
2015-2016 Research/Scholarship Committee – ACCP Cardiology PRN
2016-2017 Program Committee – Heart Failure Society of America
2018-Present American Heart Association Lifelong Learning Activity Review Group

D. Other Honors

1983 Rho Chi Honor Society
1983 Kappa Psi's Asklepios Key for service and leadership
1984 Smith Kline and French Clinical Pharmacy Award
1984 Lemmon Company Achievement Award
1991 ACCP-Glaxo Pharmacotherapy Research Award
1993 American Heart Association Grant-in-Aid Award
1994 Visiting Professor, University of Manitoba and University of Saskatchewan
1997 Fellow - American College of Clinical Pharmacy
2002 Visiting Professor, University of Montana
2007 Visiting Professor, Kalamoon University, Syria
2009 Visiting Professor, Doshisha College, Kyoto, Japan
2012 Teaching Excellence Award for College of Pharmacy
2016 Visiting Professor, Kumamoto University, Kumamoto, Japan.

E. Society officer

1994 Secretary, Cardiology PRN Group, ACCP
1995 Chair, Cardiology PRN Group, ACCP

F. Heart Failure Traineeship

2002-2009 Preceptor for ACCP Heart Failure Traineeship Program

G. Editorial Board

2011- 2014 Pharma Scientist
2012-2015 Clinical Research and Regulatory Affairs

2013-2015 Journal of Applied Biopharmaceutics and Pharmacokinetics

H. Advisory Boards

2012-2017 G2B Pharma Inc Scientific Advisor
2017-Current Cardiorespiratory Physiology Phenotyping Equipment Cluster Advisory Board. NIH Shared Instrumentation for Animal Research (SIFAR) Grant Program (S10).

I. Mentorship

2018- Current Peer Mentor ACCP Cardiology PRN (Heba Edrees)

J. Copyrights

2013 The One Minute Clinic for Heart Failure (TOM-C)

V. UNIVERSITY SERVICE

A. College of Pharmacy – University of Michigan

1989-1994 Library and Educational Resources Committee
1989-1990 Ad-Hoc Discipline Committee
1990-2000 Pharm.D. Research Committee
1992-1993 Curriculum Committee Subcommittee for Practice Faculty-Pharmacology Review
1993 Upjohn Pharmacy Research Award Committee
1993 Ad-Hoc Practice Faculty Research Resources Committee
1995 Chair - Curriculum Committee Subcommittee for Clerkship
1995-2013 Academic Standing
1995-1997 Resident Advisory Committee
1996 Chair - Curriculum Committee Subcommittee for Physical Assessment Course
1996-1999 Curriculum Committee Subcommittee for Therapeutics (P431-532)
1996-1997 Computer Subcommittee for Clinical Faculty World Wide Web Development
1997-1998 Curriculum Committee Subcommittee on Experiential Training
1997- 1999 Chair - Teaching Effectiveness Committee
1997-1998 Bylaw's Committee
1997-1998 Curriculum Committee Subcommittee on P4 Seminar
1997-1999 Research Resource Committee
1999 College of Pharmacy Ombudsman
1999 Search Committee for Department Chair
2000-2004 Curriculum Assessment Committee
2000-2001 Teaching Effectiveness Committee
2000-2003 College Executive Committee
2000-2007 Animal Committee
2002 Chair – Curriculum Committee Subcommittee on Curricular Review
2002 Chair – Therapeutic Committee
2004-2008 Departmental Research Committee
2004-2009 Therapeutics Committee
2004 Promotion Committee
2005-2007 Curriculum Committee
2005-2007 Faculty Evaluation and Development Committee
2007-2011 Chair – Curriculum and Assessment Committee
2006-2009 College Executive Committee
2007-2009 P-Care Committee
2008-2012 International Steering Committee
2008 Pre-requisite Committee – Subcommittee of the Curriculum Committee.

2009	Mission Statement and Goals Committee
2009-2015	Admissions committee – student interviewer
2009	Pharmacogenomics Committee – Subcommittee of the Curriculum Committee
2009-2012	College Steering Committee
2010-2011	Curricular subcommittee for Therapeutic Course Sequence Redesign
2011-2015	Therapeutic Problem Solving Task Force
2011	IDS Search Committee
2011	Retreat Design Committee
2011-2015	Chair - Commencement Committee
2011-2012	Curriculum Committee
2012-2014	CSAS Leadership Committee
2012-2013	Chair – Search Committee Community Pharmacy Faculty
2012	Remediation Task Force
2012-2015	Chair – International Steering Committee
2012-2015	Faculty Advisor – Student Committee for International Opportunities
2013-2015	Pharmacogenomics Committee
2013	Faculty Advisor - APhA-ASP Health Fair Training Event
2014	Faculty Advisor - APhA-ASP Health Fair Training Event
2014	Faculty - Dress for Success Fund Raiser – APhA student event
2014-2015	Chair – Faculty Expectation Committee
2014-2015	CSAS Chair Search Committee

B. University of Michigan

1994-2006	U of M General Clinical Research Center - Protocol Reviewer
1996-1999	Senate Assembly
1996	Medical Affairs Advisory Committee
1997-2000	DRG 127 - CHF Redesign Committee
1998-2001	Medical Affairs Advisory Committee
1998-2000	Heart Failure Guideline Committee
1999	Provost's Reaccreditation/student outcomes assessment Committee
1999-2000	Patient Center Focus Event Team
2004 – 2006	Heart Failure Guideline Committee
2010- 2012	Heart Failure Guideline Committee
2011-2014	Interprofessional Educational Committee – Collaborative Space Design Committee
2012	Faculty Mentor - Health Sciences Teaching Academy
2013	Faculty Mentor - Health Sciences Teaching Academy
2013-2015	Academic Affairs Committee – Senate Assembly
2013-2015	Collaborative Global Engagement Group
2013- 2014	Global Vision
2014	Provost Task Force on Engaged Learning and Digital Instruction

C. Academic, Mentoring, and other counseling – University of Michigan

1989-2000	Pharm. D. Student Advisor
2006	UM – Undergraduate Research Opportunity Program Mentor
2007	Hyun Seok Hwang – Doctorial Committee and co-mentor
2008	Fernanda Marques Burke – Doctorial Committee
2008	Michigan Institute for Clinical and Health Research – Clinical Summer Research Program Mentor
2007-2009	Mentor - K30 program for Michael Dorsch
2011-2012	Elizabeth Girnys – Doctorial Committee
2011-2015	Life Long Learning Advisor – Pharm.D. Students.
2013	Michigan Institute for Clinical and Health Research – Clinical Summer Research Program Mentor
2013	International Student Rotation – Yee Ping Chong – Bath University.

2013-2015 Monirah Albabtain – Research Fellow
2018 ACCP Mentor – E. Heba

D. College of Pharmacy – University of New Mexico

2015-Present Dean’s Executive Leadership Council
2015-Present Budget and Planning Committee
2015-Present Curriculum and Assessment Committee
2015 MS in Clinical Translational Science Committee
2015 Poster Judge – COP Research Day, Fall 2015
2015-2019 2019 Class Advisor
2015-Present Ad-Hoc Faculty Awards Committee
2016-2019 Admissions Committee
2016-2017 Chair - Pharmacy and Social Administration Graduate Program
2017 Poster Judge – COP Research Day, Spring 2017.
2017-Present Chair – PPAS Research Committee
2018 OSCE subcommittee
2018 Environmental Health Signature Pilot Award Committee
2018-Present Translational Radiopharmacy Committee
2019 APC Rubric Design Committee
2019-Present Seminar Coordinator
2019-Present Student Affairs Committee

E. University of New Mexico and University of New Mexico Health Science Center

2015-Present CTSC Sage Team Pilot Review Committee
2016 Faculty Peer Hearing
2017 CTSC KL2 Scholar Search Committee
2018-Present CTSC Multidisciplinary Advisory Committee
2018 CTSC KL2 Scholar Search Committee
2019 HSC Strategic Planning Subcommittee

F. Academic, Mentoring, and other counseling – University of New Mexico

2015-2019 Faculty Advisor – Class of 2019
2018-Present Pharm. D. Student Mentor